Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/DeltaFosB expression  by Padovan-Neto, Fernando Eduardo et al.
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6-OHDA-lesioned  rat  develops  AIMs  after  receiving  chronic  l-DOPA  treatment.
FosB/FosB  expression  increases  in  the  dopamine-depleted  striatum  induced  by l-DOPA.
Inhibitor  of  nNOS  reduced  AIMs  simultaneously  to FosB/FosB  overexpression  in  the  lesioned  striatum.
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a  b  s  t  r  a  c  t
Rodents  with  lesion  of  dopaminergic  pathway  when  receiving  repeated  l-3,4-dihydroxiphenylalanine
(l-DOPA)  treatment  develop  abnormal  involuntary  movements  called  dyskinesia.  We  demonstrated  that
nitric  oxide  synthase  (NOS)  inhibitors  mitigate  l-DOPA-induced  dyskinesia  in  rodents.  The  aim  of the
present  study  was  to  verify  if  the  in  vivo  preferential  neuronal  NOS  (nNOS)  inhibitor  7-nitroindazole
(7-NI)  affect  the  expression  of  the  transcription  factor  FosB/FosB  in  the  lesioned  striatum,  an  indi-
cator  of neuronal  activity  associated  with  dyskinesia.  Male  Wistar  rats  with  unilateral  microinjection
(medial  forebrain  bundle)  of  either  the neurotoxin  6-hydroxidopamine  (6-OHDA;  n  =  4–6/group)  or
saline  (sham;  n  = 6/group)  were  provided  with  l-DOPA  (30  mg/kg  plus  benserazide  7.5  mg/kg/day,  oral
gavage),  once  a  day  during  22  days.  6-OHDA-lesioned  animals  developed  abnormal  involuntary  move-
ments (AIMs)  classiﬁed  as  axial,  limb,  orofacial  and  locomotive  dyskinesia  and  presented  FosB/FosB
increase  in  the  dopamine-depleted  striatum.  Administration  of  7-NI  (30  mg/kg,  i.p.), 30  min  prior  to  l-yskinesia DOPA  reduced  the  severity  of  AIMs  (≈65%  for  axial,  limb  and  orofacial  and  74%  for  locomotive  AIMs
scores),  without  interfering  with  the  rotarod  performance.  Simultaneously,  7-NI  attenuated  the  expres-
sion of  FosB/FosB  in  dopamine-depleted  striatum  (≈65%  in  medial  and  ≈54%  in  lateral  striatum,  bregma
0.48 mm).  FosB/FosB  expression  in  lateral  striatum  was  correlated  with  l-DOPA-induced  dyskinesia.
The  ﬁndings  described  here corroborate  a new  approach  to  the  management  of l-DOPA-therapy  in
Parkinson’s  disease  (PD) treatment.
CrowAbbreviations: l-DOPA, l-3,4-dihydroxiphenylalanine; PD, Parkinson’s disease;
ID, l-DOPA-induced dyskinesia; SNpc, Substantia nigra pars compacta; NOS, nitric
xide synthase; l-NOARG, NG-nitro-l-Arginine; 7-NI, 7-nitroindazole; l-NAME,
G-nitro-l-Arginine-methyl esther; AIMs, abnormal involuntary movements; DA,
opamine; 6-OHDA, 6-hydroxydopamine; TH, tyrosine hydroxylase; MPTP, 1-
ethyl-4-phenyl-1,2,3,6-tetrahydropyridine.
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l-DOPA therapy remains the gold standard treatment for PD. How-
ever, l-DOPA chronic administration does not cure PD. In the
contrary, it is related with motor complications including l-DOPA-
induced dyskinesia (LID) [6,23].  Once it has been established,
dyskinesia will be induced after each l-DOPA administration,
limiting the therapeutic beneﬁt over time. Evidence from rodent
models of PD and dyskinesia provide information to better under-
stand the molecular mechanisms underlying the development of
LID [9,27].  The combined effects of progressive dopamine (DA) cell
loss in substantia nigra pars compacta (SNpc) associated with pul-
satile stimulation of dopaminergic receptors [34,35] are thought to
d. All rights reserved.
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e the major determinant of l-DOPA liability in the induction of
yskinesia.
NOS inhibitors appeared as a potential pharmacological
pproach for the treatment of LID [14]. The association of l-DOPA
nd NOS inhibitors (7-NI, NG-nitro-l-Arginine – l-NOARG, NG-
itro-l-Arginine-methyl ester (l-NAME, both nonselective NOS
nhibitor), reduced established LID with no observable motor
mpairment in rodents [36,37,46] and non-human primates
22,50]. Sub chronic administration of 7-NI reduced AIMs indicating
hat prolonged administration of 7-NI does not produce tolerance
33]. Chronic administration of l-NAME but not aminoguanidine,
ecreased LID in 6-OHDA-lesioned rats [46].
The transcription factor FosB/FosB is increased in the
odent DA-depleted striatum following l-DOPA treatment
1,8,11,32,36,38]. There is a similar pattern of FosB/FosB
xpression in patients [28,47] and 1-methyl-4-phenyl-1,2,3,6-
etrahydropyridine (MPTP)-treated monkeys [4].  Following
hronic l-DOPA exposure, FosB/FosB is selectively expressed in
ADPH-d/NOS-positive striatal neurons in parkinsonian rodents
11,38]. FosB/FosB may  regulate the expression of genes that
nduce the pathogenic cascade related to the altered motor
esponses to l-DOPA [8]. The foremost mechanism of FosB/FosB
xpression in striatal NOS-expressing neurons during LIDs is not
nown.
Here we conﬁrm that a single application of 7-NI mitigate pre-
stablished LID in 6-OHDA-lesioned rat.
Experiments were conducted according to the principles and
rocedures described by the guidelines for the care and use of mam-
als in neuroscience and behavioral research (ILAR, USA). Male
istar rats (200–250 g) were submitted to stereotaxic surgery for
icroinjection of 6-OHDA as described before [37]. Control animals
eceived saline microinjections (sham-operated). To assess lesion
ntensity, rats were tested for apomorphine (Sigma–Aldrich, USA,
.5 mg/kg, s.c.) induced rotation. 6-OHDA-lesioned rats presenting
ore than 90 rotations/45 min  were included in the study [37]. At
he end of experiment, the extension of the lesion was veriﬁed by
mmunohistochemistry for tyrosine hydroxylase (TH) at the SNpc.
6-OHDA-lesioned rats (n = 10) received daily administration of
-DOPA (30 mg/kg/day + benserazide 7.5 mg/kg/day, Prolopa dis-
ersive, Hoffman-LaRoche, Brazil) for 22 days. Axial, limb, orofacial
nd locomotor AIMs were evaluated according to a rat dyskinesia
cale [10,29,49] on the 1st, 7th, 14th, 21st and 22nd day of treat-
ent. Each rat was scored on a severity scale from 0 to 4 in each of
he four subtypes of AIMs at 1 and 2 h after l-DOPA intake dur-
ng 1 min  [37]. On the 22nd day of treatment 6-OHDA-lesioned
ats were divided into equivalent sub-groups according to the
IMs scores obtained on day 21st. Each subgroup received, 30 min
efore l-DOPA, either 7-NI (Sigma–Aldrich, USA, 30 mg/kg, “7-NI/L-
OPA”, n = 6) or its vehicle (50% polyethylene glycol-saline solution,
Veh/L-DOPA”, n = 4). 6-OHDA-lesioned (n = 6) and sham-operated
n = 6) animals that receive no treatment of any kind were used as
ontrols. 7-NI effects were obtained by between comparisons of
IMs on 22nd. Additionally, motor coordination and balance were
ested using a rota-rod (Ugo Basile, Rota-rod 7750, Italy) to exclude
ny possibility of 7-NI interference in motor behavior. Rotarod tests
speed of the acceleration from 4 to 40 rpm over a 300 s period)
ere performed 1 and 2 h after l-DOPA intake [15]. Because there
as no statistical difference between time measurement (p > 0.05,
aired “t” test) results are expressed as the average latency time
pent on the rod.
Two hours after L-DOPA administration on day 22nd rats were
erfused transcardiacally with 250 ml  of cold saline followed by
00 ml  of 4% paraformaldehyde (Sigma–Aldrich, St. Louis, MO,
SA) in 0.1 M phosphate buffer (pH 7.4). Brains were postﬁxed
t 4 ◦C C for 1 h in the above ﬁxative and cryoprotected at 4 ◦C
vernight in 0.1 M phosphate buffer (pH 7.4) with 30% sucrose.ce Letters 541 (2013) 126– 131 127
Immunohistochemistry was performed in coronal sections (25 m)
through the SNpc and striatum using a standard peroxidase based
method [19]. SNpc and striatal sections were incubated, respec-
tively, with primary rabbit polyclonal anti-TH (1:2000, Pel Freez,
Rogers, AR, USA) and rabbit polyclonal anti-FosB/FosB (1:1000,
Santa Cruz Biotechnology, USA).
Quantiﬁcations were carried out using three sections per animal
in a light microscope (Leica DMRB) equipped with a video cam-
era (Leica DFC420). Neuroanatomical sites were identiﬁed using
the atlas of Paxinos and Watson [39] and the analysis was  done
using the software ImageJ (http://rsb.info.nih.gov). DA-depletion
was  analyzed [35] in SNpc (AP: −5.8 mm and AP: −6.04 mm,  from
Bregma) [39]. FosB/Fos-B positive cells in the striatum were ana-
lyzed at levels AP: 0.48 mm  and AP: −0.92 mm (from bregma)
[39] corresponding, respectively, to rostro-medial and caudal por-
tions of striatum. Analysis was  performed in every ﬁfth section
(i.e. separated by 125 m).  In the striatum, quantiﬁcation were
done within two  adjacent areas of 286 m ×214 m (40X) and the
total number of neurons were averaged and expressed in num-
ber of cells/0.5 mm2. At rostro-medial level (AP: 0.48 mm),  four
quadrants within the dorso-medial, ventro-medial, dorso-lateral
and ventro-lateral regions were analyzed. At caudal levels (AP:
−0.92 mm)  striatum was  analyzed at dorso-lateral and ventro-
lateral quadrants. Because there was no difference between dorso-
and ventro-medial quadrants, as well dorso- and ventro-lateral
quadrants, the number of FosB/Fos-B positive nuclei in these
regions was averaged and data is expressed in terms of “medial”
and “lateral” striatum.
AIMs scores collected during chronic l-DOPA treatment were
analyzed by Friedman test followed by a Wilcoxon post hoc. Effects
of 7-NI on AIMs and rotarod performance were analyzed using
Mann–Whitney test. The 7-NI effects in the FosB/FosB expression
among the different sites of striatum were analyzed by two-way
ANOVA, with repeated measures followed by a Duncan’s post hoc.
Comparisons were done for treatments (Veh/l-DOPA and 7-NI/l-
DOPA) being side (lesioned- and unlesioned side) the repeated
measure. Statistical signiﬁcance level was  set at p < 0.05.
TH-immunostaining indicated almost complete degeneration
(>90%) of the TH-positive cell/ﬁber in the lesioned SNpc and stri-
atum. The development of axial, limb, orofacial and locomotive
AIMs (Fig. 1A and B) increased during chronic l-DOPA treatment
(p < 0.05). Corroborating our previous results, acute 7-NI (30 mg/kg)
attenuated l-DOPA-induced axial, limb and orofacial AIMs (Fig. 1C;
p < 0.05) as well as locomotive AIMs scores (Fig. 1D; p < 0.05). 7-
NI prevented l-DOPA-induced motor impairment in the rotarod by
increasing animal ability to stay in the rod (Fig. 1D; p < 0.05). The
ability of the rat stay in the rotarod was inversely correlated with
AIMs incidence (Fig. 1E and F).
As described before by Western blot [36] 6-OHDA induced an
increase in the FosB/Fos-B in the lesioned striatum as compared
to sham-operated animals (data not shown).
At the medial portion of the lesioned striatum (bregma 0.48 mm,
Fig. 2A), l-DOPA induced a signiﬁcant increase in the Fos-B/Fos-
B staining (1.6 fold) when compared to the unlesioned striatum
(side: F(1,8) = 13.79, p = 0.005; compare Fig. 3A and G). 7-NI induced
a reduction (≈65%), in the Fos-B/Fos-B immunopositive neuron
staining in the lesioned striatum (treatment: F(1,8) = 6.97, p = 0.029;
interaction: F(1,8) = 4.37, p = 0.069). In the lateral part (Fig. 2B),
there was also a signiﬁcant increase (≈43.5 fold) in the Fos-B/Fos-
B immunolabeling (side: F(1,8) = 40.50, p < 0.001; compare Fig. 3B
and H). The effects of 7-NI inducing a reduction (≈54%) in the Fos-
B/Fos-B immunopositive neuron expression (compare Fig. 3H and
K) were signiﬁcant (treatment: F(1,8) = 6.15, p = 0.038) and speciﬁc
in the lesioned striatum (interaction: F(1,8) = 6.04, p = 0.039).
At caudal level (bregma −0.92 mm,  Fig. 2C) a signiﬁcant incre-
ment (≈1.9 fold) in the Fos-B/Fos-B staining was also observed
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Fig. 1. Chronic treatment with l-DOPA to 6-OHDA-lesioned rats: development of abnormal involuntary movements (AIMs), rotarod performance and effect of 7-nitroindazole
(7-NI). l-DOPA increased over the time AIMs affecting (A) axial, limb, orofacial muscles (2(3) = 13.36, p = 0.004) as well (B) locomotive behavior (2(3) = 13.77, p = 0.003).
*p  < 0.05 vs day 1, #p < 0.05 vs day 14, +p < 0.05 vs all other days (Friedman followed by Wilcoxon, n = 10). (C) Axial, limb and orofacial AIMs and (D) locomotive AIMs were
reduced  by previous administration of 7-NI. (E) Rats’ performance on rotarod was  improved by 7-NI and (F) the time spent on the rod are plotted against the total AIMs (sum
of  axial, limb, orofacial and locomotive AIM scores). Black and white circles represent Veh/l-DOPA and 7-NI/l-DOPA-treated rats, respectively. The probability value of the
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segression (p) and the Spearman’s correlation coefﬁcient (R) are given in the top left
he  day 22. *p < 0.05 vs Veh/l-DOPA (Mann–Whitney U test; n = 4–6 per group).
side: F(1,8) = 21.10, p = 0.001; compare Fig. 3C and I) with a
arginal effect of 7-NI (treatment: F(1,8) = 2.51, p = 0.151, interac-
ion: F(1,8) = 3.07, p = 0.117, see Fig. 3I and L).
Fos-B/Fos-B expression intensity correlated with LID in medial
r = 0.81, p = 0.005, Spearman), lateral (r = 0.86, p = 0.002, Spear-
an) and caudal level (r = 0.72, p = 0.02, Spearman) portion of the
opamine depleted striatum.The result of this study support that chronic l-DOPA treat-
ent of 6-OHDA-lesioned rats induced an increase in the
osB/Fos-B-immunopositive neurons in the dopamine depleted
triatum, conﬁrming others and ours previous description [36]. Thisr. 7-NI (30 mg/kg) or it’s vehicle were administered 30 min prior l-DOPA intake on
overexpression was  attenuated in lateral portion of striatum by one
single injection of 7-NI, 30 min  before l-DOPA application (increase
of more than 43 fold followed by a 54% reduction).
In addition, it indicates an association between axial, limb
and orolingual AIMs with FosB/Fos-B labeling in the sensorimo-
tor (lateral) part of the striatum [1]. Other studies demonstrated
that lateral striatum inﬂuence the orofacial and limb movements
[5,7,16,17,24,26,41,42]. In comparison, locomotive AIMs would
mainly be linked to medial striatum [1,16].  Therefore, FosB/Fos-
B-expression and the action of 7-NI in the lesioned striatum are
related with neuroanatomical projections.
F.E. Padovan-Neto et al. / Neuroscience Letters 541 (2013) 126– 131 129
Fig. 2. Effects of 7-nitroindazole (7-NI) in the expression of Fos-B/Fos-B in the striatum. Quantiﬁcation of Fos-B/Fos-B was performed in medial and lateral areas of
lesioned- and unlesioned striatum of 6-OHDA-lesioned l-DOPA-treated rats. At bregma + 0.48 mm [39], L-DOPA induced an increment on Fos-B/Fos-B in medial (A) and
lateral  (B) portions of lesioned striatum. 7-NI was able to reduce ∼34% and ∼45% Fos-B/Fos-B overexpression in these areas respectively. At bregma −0.92 mm (C), l-
DOPA  increased Fos-B/Fos-B staining in lateral areas of lesioned striatum and this effects was not attenuated by 7-NI. *p < 0.05 (two-way ANOVA with repeated measures,
n  = 4–6/group).
Fig. 3. FosB/Fos-B-positive neuron immunolabeled nuclei in the unlesioned (upper panel) and lesioned (dopamine depleted, lower panel) striatum of 6-OHDA-microinjected
rats.  Images were taken at medial (left panel) and lateral (middle panel) portions of striatum at bregma + 0.48 mm and at lateral regions (right panel) of striatum at bregma
−0.92  mm [39]. Increments in Fos-B/Fos-B-positive nuclei were observed in lesioned striatum of dyskinetic animals (G–I, “Veh/l-DOPA”). 7-NI was able to reduce Fos-
B/Fos-B  staining (J-L, “Veh/l-DOPA”) although statistically signiﬁcance was observed only for regions analyzed at bregma 0.48 mm.  Scale bar: 100 m.
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Nitric oxide (NO) plays a main role in motor control within
he central nervous system as shown by pharmacological block-
ge and knockdown of nNOS enzyme [13,14].  Within the striatum,
O has a needed role in striatal output pathways by interac-
ing with other neurotransmitter systems [48]. Dopamine D1-like
eceptor activation [44] and electrical stimulation of nigrostriatal
eurons increased NO efﬂux in the striatum [43]. These studies indi-
ate a dopamine modulation of striatal nNOS enzyme/interneuron
ctivity via dopamine D1-like and D2-like receptor dependent
echanism [43–45].  Finally, data from our group [33,36,37,50] and
thers [22,46] that pharmacological blockage of NOS enzyme was
ble to attenuate LID without interfering with beneﬁcial l-DOPA
otor effects.
Maintenance of dyskinesia implies in plastic changes with long-
erm modiﬁcations of the basal ganglia network. The NO system
ndergoes plasticity after dopamine depletion but the relation
etween NO and LID is not understood yet [14,30,40].  Immediate
arly gene expression is proposed to be a mediator of long-term
esponse of the brain to drugs, stress and other chronic events
21], including l-DOPA administration [2,8,11,32,38].  FosB/FosB-
elated proteins are proposed to be the main postsynaptic striatal
arker for dyskinesia in rodent model of PD [1,8]. The importance
f FosB/FosB up regulation as a determinant of LID is supported
y the anti-dyskinetic effect of treatment blocking either striatal
osB/FosB induction during chronic l-DOPA administration [1]
r dyskinetic effect induced by the exacerbate expression of the
rotein [8]. Our results suggest that 7-NI attenuation of LID in
arkinsonian rodents is, at least in part, through blocking the induc-
ion of FosB/FosB expression.
Following dopamine depletion and LID induction, striatal
1-like receptor undergoes redistribution to the postsynaptic
embrane and cytoplasmic compartments [3,20,31]. FosB/FosB
s expressed in dynorphin-positive striatal neurons [1,25],  which
xpress the dopamine D1-like receptor and project into the direct
utput pathway [18]. LID is blocked in the D1-like but not D2-like
eceptors knockout mice with striatal DA depletion induced by 6-
HDA [12]. It suggests that D1-like receptor stimulation is essential
or the development of LID and the expression of the molecular
arkers such as FosB/FosB [12]. According to these results, it is
ossible that the attenuation of LID induced by 7-NI involves pref-
rentially striatal neurons of the direct pathway which express the
1-like dopaminergic receptors. More experiments are needed to
eveal the speciﬁc type of striatal neurons.
In conclusion, we show the reduction of LID in the 6-OHDA-
esioned rat striatum by nNOS inhibitor, associated with the
ttenuation of striatal FosB/FosB expression. Taken together, the
ata supports the evidence that the anti-dyskinetic effect of NO
nhibitors is, at least in part, linked to the expression of the tran-
cription factor FosB/FosB.
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